Target intelligence / Profile preview

Transcription elongation factor SPT4 (SUPT4H1)

Target
SUPT4H1
Molecular classification
Transcription factor, Transcriptional elongation factor, Nuclear protein
01

Overview

Transcription elongation factor SPT4 (SUPT4H1) is a nuclear protein encoded by the SUPT4H1 gene in humans. It forms the small subunit of the DSIF complex (with SUPT5H) that regulates transcription elongation and mRNA processing mediated by RNA polymerase II. DSIF stabilizes pausing of the polymerase near promoters, aids mRNA capping, and interacts with NELF to control transcriptional pausing; it also supports elongation reactivation and suppresses premature transcript release. Mutations or dysregulation of SUPT4H1 are implicated in inherited conditions involving transcriptional defects

Other names
SUPT4H1SPT4 homologDSIF elongation factor subunitSPT4SPT4HSUPT4HhSPT4DSIF p14DSIF small subunitSupt4aDRB sensitivity-inducing factor 14 kDa subunitDRB sensitivity-inducing factor small subunitsuppressor of Ty 4 homolog 1
02

Mechanism of action

DSIF (and thus SUPT4H1) mediates sensitivity to transcription inhibitors such as DRB by modulating RNA polymerase II elongation. The target is crucial for proper transcriptional pausing and elongation, making it a possible future target for agents affecting gene expression, though no direct drug mechanism is established for clinical agents

03

Biological functions

Regulation of mRNA processingPromotion and regulation of RNA polymerase II transcription elongationFacilitation of mRNA cappingInteraction with elongation complex components (DSIF and NELF)Promotion and regulation of transcriptional pausingInvolvement in assembly of an elongation-competent RNA polymerase II complex
04

Disease associations

Spinocerebellar ataxia 36Cockayne syndrome BOther roles in transcription-linked disorders are under investigation
05

Safety considerations

No safety concerns documented for targeting SUPT4H1 directly.The protein is essential for normal mRNA processing and gene expression; theoretical risks include unintended effects on global gene transcription or RNA metabolism if inhibited.Disruption may contribute to transcription-related genetic diseases or neurodegeneration.
06

Interacting drugs

DRB (research tool, not therapeutic)

1 more in the full profile.

07

Biomarkers

None established for patient selection or efficacy monitoring in current clinical practice or literature

Beyond the preview

Go deeper on Transcription elongation factor SPT4 (SUPT4H1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription elongation factor SPT4 (SUPT4H1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call